SYT4 binds to SNAP25 to facilitate exosomal secretion and prostate cancer enzalutamide resistance
Cancer Science · 2024
DOI: 10.1111/cas.16239 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2024. Verfasst von Budeng Huang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Hauptthemen laut MEDLINE: Phenylthiohydantoin, Benzamides, Nitriles, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The National Natural Science Foundation of China, The Natural Science Foundation of Henan Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Prostate carcinoma represents a predominant malignancy affecting the male population, with androgen deprivation therapy (ADT) serving as a critical therapeutic modality for advanced disease states, but it often leads to the development of resistance. Enzalutamide (Enz), a second‐generation antiandrogen drug, initially offers substantial therapeutic benefit, but its efficacy wanes as drug resistance ensues. In this study, we found that synaptotagmin 4 (SYT4) is an upregulated gene in enzalutamide‐resistant (EnzR) cell lines. The downregulation of SYT4, in combination with enzalutamide therapy, substantially enhances the antiproliferative effect on resistant prostate cancer cells beyond the capacity of enzalutamide monotherapy. SYT4 promotes vesicle efflux by binding to the synaptosome‐associated protein 25 (SNAP25), thereby contributing to cell resistance against enzalutamide. The elevated expression of SYT4 is mediated by bromodomain‐containing protein 4 (BRD4), and BRD4 inhibition effectively suppressed the expression of SYT4. Treatment with a therapeutic dose of enzalutamide combined with ASO‐1, an antisense oligonucleotide drug targeting SYT4, shows promising results in reversing the resistance of prostate cancer to enzalutamide.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- The 947th Army Hospital of the Chinese PLA, Kashgar, China.
ORCID-Profile: Budeng Huang, Zhankui Jia
Förderung
- The National Natural Science Foundation of China
- The Natural Science Foundation of Henan Province
- National Natural Science Foundation of China
- Natural Science Foundation of Henan Province
Zitieren
APA
Huang, B., Deng, X., Zhou, G., Li, K., Feng, Y., Xie, G., Liu, R., Song, L., Huang, Z., & Jia, Z. (2024). SYT4 binds to SNAP25 to facilitate exosomal secretion and prostate cancer enzalutamide resistance. Cancer Science. https://doi.org/10.1111/cas.16239
Vancouver
Huang B, Deng X, Zhou G, Li K, Feng Y, Xie G, et al. SYT4 binds to SNAP25 to facilitate exosomal secretion and prostate cancer enzalutamide resistance. Cancer Science. 2024. doi:10.1111/cas.16239
BibTeX
@article{Huang2024,
author = {Huang, Budeng and Deng, Xiyue and Zhou, Guochao and Li, Keqiang and Feng, Yuankang and Xie, Guoqing and Liu, Ruoyang and Song, Liang and Huang, Zhenlin and Jia, Zhankui},
title = {SYT4 binds to SNAP25 to facilitate exosomal secretion and prostate cancer enzalutamide resistance},
journal = {Cancer Science},
year = {2024},
doi = {10.1111/cas.16239}
}
EUVIMED